Endocrine dysfunctions during treatment of immune-checkpoint inhibitors | Zendy

Hidefumi Inaba | Zendy; Hiroyuki Ariyasu | Zendy; Hisako Okuhira | Zendy; Yuki Yamamoto | Zendy; Hiroaki Akamatsu | Zendy; Masahiro Katsuda | Zendy; Masatoshi Jinnin | Zendy; Isao Hara | Zendy; Takashi Akamizu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Endocrine dysfunctions during treatment of immune-checkpoint inhibitors

Author(s) -

Hidefumi Inaba,

Hiroyuki Ariyasu,

Hisako Okuhira,

Yuki Yamamoto,

Hiroaki Akamatsu,

Masahiro Katsuda,

Masatoshi Jinnin,

Isao Hara,

Takashi Akamizu

Publication year - 2018

Publication title -

trends in immunotherapy

Language(s) - English

Resource type - Journals

ISSN - 2573-5985

DOI - 10.24294/ti.v2.i2.606

Subject(s) - endocrine system , medicine , adverse effect , thyroid , immune system , endocrine gland , pancreas , oncology , bioinformatics , immunology , hormone , biology

Immune-checkpoint inhibitors (ICIs) are novel agents directed to various malignant tumors. During ICI therapy, however, immune related adverse effects (irAEs) including endocrine dysfunctions have been reported. Dysfunctions in the pituitary gland and the thyroid gland by ICI are often observed, and those in the adrenal glands and the pancreas are less frequent. Positive correlation of the prevalence of endocrine irAEs to clinical antitumor effectiveness during ICI therapy has been reported. The mechanisms of endocrine irAEs by ICI, however, remain unclear, and optimal prevention, prediction, and treatment of the irAEs are still uncertain. This review describes possible mechanisms involved in ICI-related immunity, and discusses clinical management of endocrine irAEs during ICI therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research